anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aggregated alpha-synuclein (αsyn) in oligodendrocytes (OLGs) is one of the pathological hallmarks in multiple system atrophy (MSA). We have previously reported that αsyn accumulates not only in neurons but also in OLGs long after the administration of αsyn preformed fibrils (PFFs) in mice. However, detailed spatial and temporal analysis of oligodendroglial αsyn aggregates was technically difficult due to the background neuronal αsyn aggregates. The aim of this study is to create a novel mouse that easily enables sensitive and specific detection of αsyn aggregates in OLGs and the comparable analysis of the cellular tropism of αsyn aggregates in MSA brains. To this end, we generated transgenic (Tg) mice expressing human αsyn-green fluorescent protein (GFP) fusion proteins in OLGs under the control of the 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP) promoter (CNP-SNCAGFP Tg mice). Injection of αsyn PFFs in these mice induced distinct GFP-positive aggregates in the processes of OLGs as early as one month post-inoculation (mpi), and their number and size increased in a centripetal manner. Moreover, MSA-brain homogenates (BH) induced significantly more oligodendroglial αsyn aggregates than neuronal αsyn aggregates compared to DLB-BH in CNP-SNCAGFP Tg mice, suggestive of their potential tropism of αsyn seeds for OLGs. In conclusion, CNP-SNCAGFP Tg mice are useful for studying the development and tropism of αsyn aggregates in OLGs and could contribute to the development of therapeutics targeting αsyn aggregates in OLGs.
NEW MATERIAL:A compound expressed by formula I [(m) is 1 or 2; A and R are as follows; A is formula II and R is lower alkyl, aralkyl or diaralkyl or A is formula III ((n) is 1 or 2), formula IV, etc., and R is H, lower alkyl, aralkyl or diaralkyl]. EXAMPLE:9-Amino-1,2,3,4,5,6,7,8-octahydro-1,4-methanoacridine. USE:A treating agent for senile dementia having excellent acetylcholine esterase inhibitory action. PREPARATION:A compound expressed by formula V is reacted with a compound expressed by formula VI, etc., in the presence of a Lewis acid (e.g. anhydrous aluminum chloride) in a solvent, such as nitrobenzene, at 50 to 150 deg.C to afford the compound expressed by formula I (R is H). Furthermore, alkylation, aralkylation or diaralkylation reaction, as necessary, is carried out.
The physician providing treatment will use, depending on his professional judgment for each subject, one of four treatment modalities: (1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method. These modalities are standard to the care and practice of osteopathic manual medicine, they are taught in the Osteopathic curriculum, and they are practiced each day at the Michigan State University Clinical Center.

After the initial treatment, there will be an immediate follow-up kinematic test to collect the 3-D motion data. Then, subjects will return for subsequent kinematic assessments at: 24 hours post treatment, 48 hours post treatment and seven days post treatment. At the seven day mark, subjects will be evaluated as in the initial assessment and the physician will use his professional judgment to determine if the subject would benefit from a second treatment. If so, then the process of treatment and kinematic assessment would occur a second time, with kinematic assessment 24 hours post treatment, 48 hours post treatment and seven days post treatment. A maximum of two treatment sessions will be performed.
As the worldwide incidence of diabetes increases, the search for dietary adjuncts to treat this life-altering disease becomes far ranging. Cinnamon is purported to be a natural insulin sensitizer without any known adverse events. Both in vitro and in vivo animal studies have shown that cinnamon is an insulin sensitizer1. Several compounds within cinnamon have been identified as possible sources of this sensitization process.

To-date, three small randomized trials studying cinnamon in human diabetics have been published. Khan et al. reported that fasting serum glucose could be reduced by 18-29% after 40 days of supplementation with 1, 3, or 6 g of cinnamon (Cinnamomum cassia) in type 2 diabetics. 2 This study had several limitations that included failure to measure hemoglobin A1C, all patients were Pakistani, and no power analysis was documented. Vanschoonbeek, et al.3 report a small RCT of postmenopausal women with well-controlled type 2 diabetes which showed no change in HbA1C or fasting glucose. Once again no power analysis is reported. Mang et al. 4 conducted a RCT of type 2 diabetics treated with aqueous extract of cinnamon for 4 months. They report a 15% decrease in fasting glucose and no change in HbA1C over the duration of this trial. Subjects had HbA1C less than 7% and again no power analysis was included in this study.

This study will address whether cinnamon at the dose of 1g daily in addition to usual care lowers hemoglobin A1c compared to usual care. Power analysis indicates that 63 per group are needed and we will recruit 70 patients.
PURPOSE:A pack, containing an acidic buffer agent in a base which is a fat or oil absorbing powder, having high fat absorptivity and improved makeup durability, and capable of giving a wide feeling of use ranging from dry to moist touch. CONSTITUTION:A pack containing 0.5-5.0% concentration buffer agent in a base consisting of fat or oil absorbing powder which is an inorganic powder, e.g. talc, kaolin, silicic acid anhydride or calcium carbonate, a spherical or amorphous organic powder, e.g. nylon, PVC or polyproplylene, or a suitably hydrophilized powder thereof. The acidic buffer agent preferably has 3.0-5.0pH of an aqueous solution thereof, and lactic acid-sodium lactate, sodium citrate-hydrochloric acid and succinic acid-borax, etc. may be used.
A solid co-amorphous dispersion of valsartan according to the invention is characterized in that in the amorphous solid phase it contains valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, an d at least one non-toxic amphiphilic solvent that solvates valsartan and co-former molecules, wherein the content of valsartan exceeds 40 mol % and 65 wt %, and the dispersion exhibits an increased water solubility - with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. A method for synthetizing a solid co-amorphous dispersion of valsartan by mixing valsartan with a co-former, pouring a solvent over the mixture and evaporating the solvent, wherein the physical mixture of valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, and at least one non-toxic amphiphilic solvent is formed and subjected to mixing and homogenization in a condensed- phase, at the temperature range of 20-100°C, preferably 45-100°C, whereby excess of the solvent used is stripped off at the temperature range of 20-100°C, preferably 45-100°C, to give a final product in form of a solvated solid co-amorphous dispersion of valsartan, co-former and the solvent, which dispersion exhibits an increased water solubility - with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. The use of solvated solid co-amorphous dispersions of valsartan as described above, obtained as described above, in medicine and pharmacy, especially for treatment of hypertension and COVID-19 disease caused by SARS-CoV-2 virus, as a ternary formulation of valsartan, nicotinamide and a non-toxic amphiphilic solvent, preferably ethanol, n-propanol or i-propanol, characterized by increased water solubility - with respect to valsartan contained therein, in comparison with the solubility of pure valsartan, and having a dual action, resulting from the synergy of ingredients supporting the therapeutic effect of valsartan. The disclosed solid dispersion according to the invention is characterized by higher solubility in comparison with that of pure valsartan, and therefore an increased bioavailability of this drug. A number of benefits results therefrom for patients (lower amount of active substance ingested), the pharmaceutical industry (lower effective dose of the active substance in preparations, resulting in reduction of production costs) and the environment (less amount of the active substance and its metabolites not absorbed by patients and released into the environment). The appropriate selection of excipients allows for the use of the dispersion according to the invention as a drug of dual-activity, in treatment of hypertension and in treatment of SARS-CoV-2 coronavirus infection causing COVID-19 disease.
Patients complete a treatment decision counseling session/interview about genetic testing and supportive/palliative care with a qualified member of the research team in-person or via telephone. Health care providers receive a 1-page summary of session results for use in treatment shared decision making at the next office visit.
The control device appears identical to the active device, but utilizes 9 LED lights instead of laser lights. The randomized devices are blinded to the study investigator and distributed in a blinded manner to the participants.
Sharing neuroimaging datasets enables reproducibility, education, tool development, and new discoveries. Neuroimaging from many studies are publicly available, providing a glimpse into progressive disorders and human development. In contrast, few stroke studies are shared, and these datasets lack longitudinal sampling of functional imaging, diffusion imaging, as well as the behavioral and demographic data that encourage novel applications. This is surprising, as stroke is a leading cause of disability, and acquiring brain imaging is considered standard of care. The first release of the Aphasia Recovery Cohort includes imaging data, demographics and behavioral measures from 230 chronic stroke survivors who experienced aphasia. We also share scripts to illustrate how the imaging data can predict impairment. In conclusion, recent advances in machine learning thrive on large, diverse datasets. Clinical data sharing can contribute to improvements in automated detection of brain injury, identification of white matter hyperintensities, measures of brain health, and prognostic abilities to guide care.
The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of α-aminoisobutyric acid (AIB) analogs namely, their rapid uptake and prolonged retention in tumors with the properties of halogen sustituents, including certain useful halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. In addition the compounds can be labeled with technetium and rhenium isotopes using known chelation complexes. The amino acid compounds disclosed herein have a high specificity for target sites when administered to a subject in vivo. Preferred amino acid compounds include [18F] FAMP, ([18F]5a) and [18F]N-MeFAMP, ([18F]5b). The invention further features pharmaceutical compositions comprised of an α-amino acid moiety attached to eiher a four, five or a six member carbon-chain ring. The labeled amino acid compounds are useful as imaging agents in detecting and/or monitoring tumors in a subject by Positron Emission Tomography (PET) and Single Photon Emission Computer Tomography (SPECT).
Procedure for obtaining formula I acyclovir and its hydrates, which includes the reaction of tris-(N<2>,0,9-trimethylsilyl) guanine with 2-oxa-1,4-butanodiol diacetate, giving rise to a formula IV compound through hydrolysis of the reagent solution:< IMAGE >which then reacts with a base in a solvent to obtain the formula I compound. Acyclovir is an antiviral agent with low cytotoxicity used in therapy to treat infections caused by the herpes virus.< IMAGE >The guanine deriv. Acyclovir of formula (I) and its hydrates are obtd. by reacting tris-(N2.O.9-trimethylsilyl) guanine with 2-oxa 1,4-butane diol diacetate and hydrolysis of the crude prod. to give cpd. of formula (IV). This is reacted with a base in presence of solvent to obtain (I).
Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention. The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check. A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness. Participants will be directed to the PC for technical problems.
BACKGROUND: Within the pediatric population, a positive self-concept is associated with better academic achievement. Children with chronic kidney disease (CKD) are at risk for lower quality of life and academic underachievement. Little is known about self-concept among children with CKD and how self-concept influences academic achievement. The objectives of the present study were to (1) describe patient-reported self-concept among children with CKD and (2) evaluate the relationship between self-concept and academic performance.
METHODS: This cross-sectional study included 23 children, aged 6-16 years, with mild to moderate CKD (cause of disease due to congenital anomalies of the kidney and urinary tract) and 26 age-matched comparators. Participants completed the Self-Description Questionnaire (SDQ) and the Wide Range Achievement Test (WRAT-4). Linear regression models were used to evaluate self-concept as a predictor of academic achievement in the CKD cohort.
RESULTS: Self-concept ratings were comparable between children with CKD and non-CKD comparators; however, academic achievement trended lower for the CKD patients on measures of arithmetic (estimate =  - 0.278, 95% confidence interval (CI) [- 0.530: - 0.026], t(45) =  - 1.99, p = 0.053). All of the SDQ domains predicted WRAT-4 arithmetic performance, such that higher scores on the SDQ were associated with higher scores in mathematics. Kidney function did not have an effect on the relationship between self-concept and academic achievement.
CONCLUSIONS: Despite the presence of a chronic disease, children with CKD endorse a positive self-concept. Positive self-concept may predict academic success in this population.
The invention relates to an oral Chinese medicinal preparation for treating blood stasis type gastric ulcer. The oral Chinese medicinal preparation comprises the following raw materials in part by weight: 20 parts of root of red-rooted salvia, 20 parts of Chinese angelica, 15 parts of hide glue, 15 parts of nutgrass galingale rhizome, 15 parts of longstamen onion bulb, 10 parts of notoginseng root, 10 parts of trogopterus dung, 20 parts of rhizoma corydalis, 15 parts of turmeric root-tuber, 15 parts of costustoot, 15 parts of root of straight ladybell and 10 parts of dendrobium. The preparation comprises all clinically acceptable formulations applicable to oral administration, preferably powder, capsules and pills. The selected raw materials have the effects of nourishing stomach and generating body fluid, activating blood and relieving pain, relaxing bowel, and soothing the liver and regulating vital energy. Clinical application proves that the oral Chinese medicinal preparation has ideal treatment effect on the blood stasis type gastric ulcer. The oral Chinese medicinal preparation has the advantages of obvious curative effect, low treatment cost, and no toxic or side effect.
INTRODUCTION: A cupulolithiasis of the lateral semicircular canal is an accumulation of otolithic debris at the level of the cupula of the same canal. Its pathophysiology generally generates a specific clinical presentation. This situation can be very disabling for the patient and tricky to treat for the clinician.
CASE REPORT: The patient was a 70-year-old man with cupulolithiasis of the right lateral semicircular canal. We present here the conversion of cupulolithiasis to canalolithiasis using the Thomas Richard Vitton (TRV) repositioning chair, as well as the treatment of this canalolithiasis through a mechanical liberation maneuver.
CONCLUSION: The results of manual therapeutic maneuvers for Benign Paroxysmal Positional Vertigo (BPPV) are generally good regardless of the type of BPPV. It can sometimes be more challenging to resolve an ageotropic-type BPPV of the lateral semicircular canal and mechanically-assisted maneuvers using a repositioning chair may be required. Faced with symptom resistance despite attempts at multiple liberatory maneuvers, clinicians must be able to reconsider their initial diagnosis and investigate other potentially more serious origins of these symptoms. The TRV chair can be a treatment option in the management of cupulolithiasis, especially in cases where classic reduction maneuvers do not always yield good results.
PURPOSE:To accomplish freeze-concentration in a convenient manner without the need for strict temperature control by adding microorganisms having ice- nucleation activity to a solution of water-soluble material to be concentrated followed by cooling to a level not higher than the ice-freezing point. CONSTITUTION:When a material liable to induce deterioration or vaporization loss (e.g. enzyme, soluble protein such as egg, brewed product such as wine, favorite food such as coffee) is to be concentrated, microorganisms having ice-nucleation activity is used as ice crystallization nuclei to carry out freeze- concentration. Said microorganisms is e.g. those classified as Erwinia sp. (e.g. Erwinia ananas) or Pseudomonas sp. (e.g. Pseudomonas syringae). To use the microorganisms as ice crystallization nunclei, the microorganisms or fragments thereof crushed by supersonic wave are added to a solution to be concentrated or coated on the wall of the container; however, use of such microorganisms in the immobilized form with e.g. alginic acid gel is preferable in terms of the separation and reuse thereof.
Infants in the patterned experience group will receive a patterned feeding experience with all feedings through discharge. They will receive a touch intervention at each gavage feeding. Once oral feedings are initiated, they will be offered an oral feeding at every scheduled feeding. They will be held for feedings. They will be observed twice a week utilizing the computer data acquisition system. Follow up visits will occur at 2,6 amd 24 months corrected age.
Patients with grade B / C, stage III periodontitis were classified based on the new classification criteria.Clinical attachment loss ≥5 mm, probing depth (PD) ≥6 mm, ≥20 teeth and radiographic bone loss extending to the root middle third. Grade was assessed considering the radiographic bone loss in the most affected tooth in the dentition as a function of age (Grade B=0.25-1.0, Grade C= \>1.0).
The invention discloses a metallic thiophene ring ternary complex with anti-cancer activity. The complex has a chemical formula: RE(TTA)3L.nH2O(n=1-7) or Mt2(TTA)3L.Cl4. The complex has good chemical stability and thermal stability and can be used, stored and transported at a normal temperature. The ternary complex is 0.005 to 0.5 mu g/ml for the IC50 of a promyelocytic leukemia tumor cell, has a nanometer grade grain size range, and more easily enters and kills the cancer cell. In addition, the preparation method is simple, and has low preparation price, and little impact on the environment in a manufacturing link. The ternary complex has high biological availability and little dosage, and brings about less drug toxicity.
This retrospective study analyzed a case series of female sexual violence (SV) victims who were admitted to the emergency department of the University Hospital in Udine between January 2012 and April 2023. A total of 155 cases were divided into two groups according to their age: 115 adult victims and 40 minors. Compared with minors, adults had risk factors such as psychiatric disorders and past experience of SV, and reported bodily injuries and extragenital lesions more frequently. Moreover, a positive screening for sexually transmitted diseases and its association with genital injuries turned out to be significantly more present among adult victims than minors. In contrast, victims younger than 18 years tended to delay seeking medical help and more often did not report genital penetration. To conclude, a deeper knowledge of the different characteristics of sexual abuse among female adults and minors may help us to understand what the focus of prevention programs and public awareness campaigns should be.
BACKGROUND: Pulsed-dye lasers (PDL) are one of the standard therapies for rosacea, but alternatives are needed.
AIMS: To compare the efficacy and safety of the variable-sequenced, large-spot 532 nm KTP laser to the 595 nm PDL in treating rosacea.
MATERIALS AND METHODS: A prospective, controlled, evaluator-blinded study. Patients were treated with either a KTP or PDL with 1-3 sessions at intervals of 6-8 weeks. A follow-up visit was scheduled on Week 6 post-treatment. Clinical outcome was assessed by computer-assisted analysis and by patients and two blinded dermatologists. Pain intensity during treatment and adverse events were documented.
RESULTS: Forty-five patients (mean age 51 years) were allocated in a 2:1 ratio to either the KTP or PDL. Erythema in both treatment arms decreased significantly (p < 0.01). Clinical evaluation revealed high improvement. Mean pain intensity was significantly lower with the KTP (2.5/10) than with the PDL (4.1/10). Both lasers showed a good safety profile. Relevant purpura was only seen in the PDL group.
CONCLUSIONS: Both the variable-sequenced, large-spot KTP and the PDL demonstrated comparable efficacy in treatment of rosacea. Regarding safety, the KTP exhibited fewer post-treatment reactions. The KTP might serve as a potential alternative to PDL in the treatment of rosacea.
The participants were instructed to take a bath once a day using a syndet bar and to towel dry their skin before applying the akapulko decoction. Fresh decoction was prepared by the patients every day. After a bath, the patient applied the fresh cooled decoction by hand on the whole body especially on the affected areas and left it to dry. Approximately one glassful (350ml) of akapulko decoction should be consumed for one whole body application. The total duration of daily application should be 4 weeks (28 days +3) until the next outcome assessment.The patients were given illustrated, laminated instructional materials and a tabulated checklist of instructions on how to prepare and apply the decoction which served as a monitoring sheet of each patient.
Study drugs were administered intravenously on the first day of each cycle. Administered sequentially: carrelizumab, 200mg/time, paclitaxel, 50mg/m2, cisplatin, 25mg/m2, chemotherapy once a week, a total of 5 doses, carrelizumab every three weeks until PD or intolerable, up to 2 years, simultaneous radiotherapy at the first dose, the total dose of radiotherapy is 50.4Gy, completed in 28 divided doses, 1.8Gy each time, 5 times a week.